S160: MOLECULAR DETERMINANTS OF DISEASE PROGRESSION AFTER HYPOMETHYLATING AGENT THERAPY IN RAS PATHWAY MUTANT CHRONIC MYELOMONOCYTIC LEUKEMIA AT THE SINGLE-CELL LEVEL

• G. Montalban-Bravo,
• F. Ma,
• I. Ganan-Gomez,
• R. Kanagal-Shamana,
• V. Adema,
• N. Thongon,
• H. Yang,
• K. A. Soltysiak,
• C. Bueso-Ramos,
• H. Kantarjian,
• G. Garcia-Manero,
• S. Colla

Affiliations

G. Montalban-Bravo

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

F. Ma

2 Molecular Biology Institute, University of California, Los Angeles

I. Ganan-Gomez

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

R. Kanagal-Shamana

3 Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, United States of America

V. Adema

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

N. Thongon

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

H. Yang

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

K. A. Soltysiak

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

C. Bueso-Ramos

3 Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, United States of America

H. Kantarjian

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

G. Garcia-Manero

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston

S. Colla

1 Leukemia, The University of Texas MD Anderson Cancer Center, Houston